Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to 0.37.

  • Mirum Pharmaceuticals' Equity Ratio rose 707.6% to 0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37, marking a year-over-year increase of 707.6%. This contributed to the annual value of 0.34 for FY2024, which is 1252.6% down from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Equity Ratio stood at 0.37 for Q3 2025, which was up 707.6% from 0.35 recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Equity Ratio high stood at 0.6 for Q1 2021, and its period low was 0.18 during Q2 2023.
  • Its 5-year average for Equity Ratio is 0.37, with a median of 0.37 in 2022.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Equity Ratio crashed by 7170.93% in 2021, and later surged by 9555.77% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Equity Ratio (Quarter) stood at 0.41 in 2021, then dropped by 1.35% to 0.4 in 2022, then fell by 4.45% to 0.38 in 2023, then fell by 12.53% to 0.34 in 2024, then grew by 10.58% to 0.37 in 2025.
  • Its Equity Ratio stands at 0.37 for Q3 2025, versus 0.35 for Q2 2025 and 0.34 for Q1 2025.